- Conditions
- Glaucoma
- Interventions
- SENSIMED Triggerfish
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–756
of 756
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glaucoma, Primary Open Angle
- Interventions
- ELIOS Procedure
- Device
- Lead sponsor
- Elios Vision, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more
- Conditions
- Primary Open Angle Glaucoma (POAG)
- Interventions
- Direct Selective Laser Trabeculoplasty
- Device
- Lead sponsor
- Select Eye Care
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Elkridge, Maryland
- Conditions
- Primary Open-angle Glaucoma
- Interventions
- iStent inject, Cataract surgery
- Device · Procedure
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Racine, Wisconsin
- Conditions
- Glaucoma
- Interventions
- XEN-45 Gel Stent, Trabeculectomy
- Device · Procedure
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 35
- States / cities
- Fayetteville, Arkansas • Arcadia, California • Culver City, California + 31 more
- Conditions
- Open-angle Glaucoma or Ocular Hypertension
- Interventions
- DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
- Drug · Other
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Xen Gel Stent
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Raised Intraocular Pressure
- Interventions
- AZD4017, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Atlanta, Georgia • Morrow, Georgia + 4 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma
- Interventions
- Ripcord removal
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Elevated Intraocular Pressure (IOP)
- Interventions
- Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug
- Combination Product
- Lead sponsor
- Mati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
- Interventions
- SENSIMED Triggerfish®
- Device
- Lead sponsor
- Sensimed AG
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New York, New York